BOULDER, CO--(Marketwired - Oct 22, 2014) - Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"), a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, ultra-low THC, cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is extremely pleased to announce the launch of its all-new Canna-Pet™ commercial website (www.canna-pet.com).
Moving quickly to maximize the current and potential interest in cannabidiol (CBD) based pet supplements, Cannabis Therapy Corp. has quickly seized on existing customer momentum as the basis for the redevelopment of the Canna-Pet™ online sales portal. The website was redeveloped in an effort to improve its functionality and customer support, and to integrate proven digital marketing strategies as a means of seeking to boost sales and resulting revenues.
Sales resulting from launch of the website will result in the immediate receipt of revenues from operations for Cannabis Therapy Corp, which is the exclusive worldwide license holder for sales of Canna-Pet™ products. Revenues will be reported as part of the Company's ongoing regulatory disclosure in its Q1 2015 quarterly earnings report.
Cannabis Therapy Corp. President and CEO Dr. Soren Mogelsvang states, "This is a milestone event in the very short timeline since the inception of our Company. Not only are we generating revenues, but we are also capturing exceptional business intelligence as regards the marketing, sales and distribution of hemp based and CBD enhanced products. To-date, our industry is in its infancy and relatively uncharted, which led us to determine that initiating commercial activities within the recession-proof pet health sector would offer extraordinary promise for growth within the shortest possible timeframe. Insofar as we remain firmly focused on the development of human therapies, we believe Canna-Pet™ offers sustainable and predictable growth while offering a profoundly gratifying service to our customers, and is already well on the way to achieving an excellent projected return on our investment in as little as 6 months based on all early indications."
For more information about Cannabis Therapy Corp. please visit www.cannabistherapy.com.
Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.cannabistherapy.com.
About Cannabis Therapy Corp. (OTCQB: CTCO)
Cannabis Therapy Corp. aims to develop and market safe, phytocannabinoid-based medicinal products and to apply rigorous manufacturing and quality control standards to become a global leader in the research, development, manufacturing, testing and marketing of cannabinoid ingredients and therapies for both humans and animals. For more information visit www.cannabistherapy.com.
About Canna-Pet™ Products for Pet Health
Developed in an international collaboration of scientists, medical researchers, and veterinarians, Canna-Pet™ is one of the first legal cannabinoid (CBD) product designed specifically for cats and dogs. Available over-the-counter, Canna-Pet™ produces veterinarian recommended, legal, cannabidiol (CBD) products for animals, made from industrial hemp and manufactured in the USA. Canna-Pet® products contain not only CBD, but carefully controlled ratios of other cannabinoids and terpenes which make the products uniquely effective. Now available under an exclusive commercial license agreement with Cannabis Therapy Corp. (OTC: CTCO). For more information visit: www.canna-pet.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.
ON BEHALF OF THE BOARD,
Soren Mogelsvang, President & CEO
Cannabis Therapy Corp.